Development and Validation of a Pathomics-Based Prognostic Model for Patients with Lung Adenocarcinoma Undergoing First-Line EGFR-TKI Therapy.

Background: Accurate prognostic prediction is crucial for personalized treatment of patients with lung adenocarcinoma (LUAD) receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This study aims to develop and validate a pathomics-based prognostic model for EGFR-TKI-treated patients with LUAD.

Patients And Methods: Data from 122 patients with LUAD who underwent first-line EGFR-TKI therapy were retrospectively analyzed.